Synergistic Mitophagy Activation by Urolithin A and Spermidine via Calcium‑Dependent Histone Acetylation and Translational Enhancement

Hypothesis

Combined supplementation with urolithin A (UA) and spermidine produces a synergistic activation of mitophagy that exceeds the additive effects of each compound alone, driven by calcium‑dependent calmodulin kinase II (CaMKII)–mediated histone acetylation and spermidine‑induced eIF5A hypusination, which together amplify TFEB‑driven lysosomal biogenesis and autophagosome‑lysosome fusion.

Mechanistic Rationale

UA triggers ER calcium release via InsP3R and mitochondrial uptake through MCU, activating DRP1‑mediated fission and the AMPK‑PINK1/Parkin axis 1. Beyond these pathways, the calcium surge stimulates CaMKII, which phosphorylates the histone acetyltransferase GCN5, increasing acetylation of H3K9 at promoters of lysosomal and autophagy genes (e.g., LAMP1, CTSB). Simultaneously, spermidine promotes the hypusination of eukaryotic translation initiation factor 5A (eIF5A), enhancing translation of TFEB‑target mRNAs and autophagy‑related proteins such as LC3 and ATG5 5. The convergence of increased chromatin accessibility (UA arm) and boosted translational capacity (spermidine arm) creates a feed‑forward loop that amplifies TFEB nuclear translocation and lysosomal gene expression beyond what either metabolite achieves alone.

Predictions

1. In human peripheral blood mononuclear cells (PBMCs) stratified by UA‑producer status (high vs. low), the combination UA + spermidine will yield a greater increase in mitophagy flux (measured by mt‑Keima assay) than the sum of the individual treatments.
2. This synergistic effect will be accompanied by (a) higher nuclear TFEB levels, (b) increased H3K9ac at lysosomal gene promoters, and (c) elevated eIF5A hypusination, all detectable by immunoblot or immunofluorescence.
3. Microbiome‑derived urolithin levels will correlate with baseline CaMKII activity, whereas spermidine response will be independent of UA‑producer status, allowing the combination to rescue mitophagy in low‑UA producers.

Experimental Design

• Recruit 60 healthy middle‑aged volunteers, classify them as high or low UA producers based on fecal urolithin A metabolite profiling after a standardized ellagitannin challenge.
• Isolate PBMCs and treat in triplicate with: vehicle, UA (10 µM), spermidine (5 µM), UA + spermidine (same concentrations) for 6 h.
• Measure mitophagy flux using mt‑Keima flow cytometry, lysosomal activity (LysoTracker), TFEB subcellular localization (immunofluorescence), H3K9ac (ChIP‑qPCR at LAMP1 promoter), and eIF5A hypusination (Western blot with anti‑hypusine).
• Include controls: CaMKII inhibitor (KN‑93) and GCN5 inhibitor (CPTH2) to test dependence on the calcium‑CaMKII‑GCN5 axis.

Potential Outcomes and Falsifiability

• Support: UA + spermidine yields >1.5‑fold increase in mitophagy flux versus the additive prediction, accompanied by synergistic rises in TFEB nuclear translocation, H3K9ac, and eIF5A hypusination; inhibition of CaMKII or GCN5 abolishes the UA‑driven chromatin component, while eIF5A hypusination inhibition reduces the translational boost.
• Refute: No significant difference between combination and the best single agent, or lack of correlated increases in the proposed molecular readouts; or inhibition of CaMKII/GCN5 does not affect the combination’s efficacy, indicating the calcium‑dependent histone acetylation axis is dispensable.

By directly linking UA‑evoked calcium signaling to epigenetic priming and positioning spermidine as a translational enhancer, this hypothesis offers a concrete, testable framework for designing microbiome‑informed, combinatorial postbiotic strategies to counteract age‑related mitophagy decline.